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Novelty and Impact:  
Risk factor profiles by ovarian cancer subtypes defined by disease aggressiveness (time between diagnosis and 
death), were investigated under the hypothesis that these profiles are associated with tumor aggressiveness 
independent of histology. Risk factor profiles for the most aggressive disease categories clustered together 
independent of histotype suggesting that risk profiles may be directly associated with subtypes defined by tumor 
aggressiveness, rather than through differential effects on histology, providing impetus for future studies on 
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Abstract  
Ovarian cancer risk factors differ by histotype; however, within subtype there is substantial variability in 
outcomes. We hypothesized that risk factor profiles may influence tumor aggressiveness, defined by time 
between diagnosis and death, independent of histology.  Among 1.3 million women from 21 prospective 
cohorts, 4,584 invasive epithelial ovarian cancers were identified and classified as highly aggressive (death in 
<1 year, n=864), very aggressive (death in 1-<3 years, n=1,390), moderately aggressive (death in 3-<5 years, 
n=639), and less aggressive (lived 5+ years, n=1,691). Using competing risks Cox proportional hazards 
regression, we assessed heterogeneity of associations by tumor aggressiveness for all cases and among serous 
and endometrioid/clear cell tumors. Associations between parity (phet=0.01), family history of ovarian cancer 
(phet=0.02), body mass index (BMI; phet≤0.04) and smoking (phet<0.01) and ovarian cancer risk differed by 
aggressiveness. A first/single pregnancy, relative to nulliparity, was inversely associated with highly aggressive 
disease (HR: 0.72; 95% CI [0.58-0.88]), no association was observed for subsequent pregnancies (per 
pregnancy, 0.97 [0.92-1.02]). In contrast, first and subsequent pregnancies were similarly associated with less 
aggressive disease (0.87 for both). Family history of ovarian cancer was only associated with risk of less 
aggressive disease (1.94 [1.47-2.55]). High BMI (≥35 vs. 20-<25 kg/m
2
, 1.93 [1.46-2.56] and current smoking 
(vs. never, 1.30 [1.07-1.57]) were associated with increased risk of highly aggressive disease. Results were 
similar within histotypes. Ovarian cancer risk factors may be directly associated with subtypes defined by tumor 
aggressiveness, rather than through differential effects on histology. Studies to assess biological pathways are 
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Introduction 
 Ovarian cancer is one of the most fatal cancers in women, with over 150,000 deaths globally per year 
1
. 
The five-year relative survival for ovarian cancer patients is about 45%, while the ten-year relative survival is 
only slightly lower at 35%.
2, 3
 Further, across all stages of disease, the probability of surviving the next five 
years increases with longer survival.
4
 This, in conjunction with data showing worse outcomes for high-grade 
serous tumors compared to other types,
5-7
 suggests that some tumors may be intrinsically more aggressive than 
others. While differences in survival across tumor subtypes can be explained, in part, by surgical outcomes,
8
 a 
recent study noted that changes in chemotherapy regimens did not substantially influence long-term survival.
9
 
More recently, studies have shown that exposures before diagnosis are differently associated with ovarian 
cancer subtypes 
10-14
, with each histologic type showing a distinct pattern of risk factor associations.
10
 However, 
few studies have considered whether risk factor profiles may influence the development of ovarian cancer 
toward more aggressive (i.e., rapidly fatal) versus less aggressive subtypes. 
 One prior study that combined data from two prospective cohort studies (also included in the present 
study) and two case-control studies used time to death as a surrogate for characterizing more versus less 
aggressive disease (i.e., death within 3 years of diagnosis compared with longer survival).
15
 Multiple established 
ovarian cancer risk factors, including age, parity, oral contraceptive (OC) use, and menopausal status, were 
differentially associated with risk by tumor aggressiveness for all invasive and serous tumors. For example, 
each birth was associated with a significant 13% lower risk of less aggressive disease but only a 2% lower risk 
for more aggressive tumors, although the first birth was associated with a similar ~20% lower risk of both 
tumor types. We expanded this analysis within the Ovarian Cancer Cohort Consortium (OC3), which included 
21 prospective cohort studies across Australia, Europe, Asia, and North America. With 4,584 invasive ovarian 
cancer cases, we examined the relationship of 17 established and putative risk factors by tumor aggressiveness 
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Study population 
The OC3 includes women participating in 23 prospective cohort studies, 21 of which had sufficient 
cases and follow-up for death (defined as at least 3 years of follow-up for >50 cases) to be included in this 
analysis (Table 1). Studies were required to have prospective follow-up for incident cases of ovarian cancer 
through questionnaires, medical records or cancer registries, as well as follow-up for death, along with data on 
age at study entry, OC use, and parity. Women with a history of cancer (other than non-melanoma skin cancer), 
with bilateral oophorectomy prior to study entry, or missing age at baseline were excluded. All studies obtained 
institutional approval for cohort maintenance as well as participation in the OC3. The OC3 Data Coordinating 
Center and analytic approaches were approved by the institutional review board of the Brigham and Women’s 
Hospital (BWH). 
Exposure assessment 
Full baseline cohort data (19 studies) and case-cohort datasets with weights for subcohort members (2 
studies) were centrally harmonized. We examined multiple ovarian cancer risk factors, including parity (no 
children, first child, linear term for subsequent children), age at first birth (per 1 year; and <20, 20-<25, 25-<30, 
30+ years), age at last known birth (per 1 year; <25, 25-<30, 30-<35, 35+ years), duration of OC use (per 5 
years of use; never, ≤1, >1-≤5, >5-≤10, >10 years), duration of breastfeeding (per 1 year; ever vs. never among 
parous women), age at menarche (per 1 year; ≤11, 12, 13, 14, ≥15 years), age at natural menopause 
(postmenopausal women only: per 5 years; ≤40, >40-≤45, >45-≤50, >50-≤55, >55 years), duration of 
menopausal hormone therapy (HT) use (postmenopausal women only: per 1 year; never, ≤5, >5 years), tubal 
ligation (yes vs. no), hysterectomy (yes vs. no), endometriosis (yes vs. no), first degree family history of breast 
cancer (yes vs. no), first degree family history of ovarian cancer (yes vs. no), BMI at baseline (per 5 kg/m
2
; <20, 
20-<25, 25-<30, 30-<35, ≥35 kg/m
2
), BMI at age 18-20 years (per 5 kg/m
2
; <18, 18-<20, 20-<22, ≥22 kg/m
2
), 
height (per 0.05m; <1.60, 1.60-<1.65, 1.65-1.70, ≥1.70 m), and smoking at baseline (never, former, current). 
Studies that did not provide data on a specific risk factor were excluded from the analysis of that factor, leading 
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Outcome definition 
Epithelial ovarian or peritoneal cancer cases were confirmed through cancer registries or medical record 
review (ICD9: 183, 158; ICD10: C56); details were described previously.
10
 For each case, we requested 
information on date of or age at diagnosis, histology (classified as serous/poorly differentiated, endometrioid, 
mucinous, clear cell, other/unknown), and date of or age at death (if applicable). All studies obtained 
information on deaths during the course of follow-up, primarily through mortality registries and family 
members, and had >95% mortality follow-up. We calculated the time between diagnosis and death for all cases 
who died and classified tumors as highly aggressive (death in <1 year, n=864), very aggressive (death in 1-<3 
years, n=1,390), moderately aggressive (death in 3-<5 years, n=639), and less aggressive (lived 5+ years, 
n=1,691). For cases who did not die during follow-up, we excluded those who had less than 5 years of follow-
up time after diagnosis (n=992).  
Statistical methods 
We calculated hazard ratios (HR) and 95% confidence intervals (95% CI) using competing risks Cox 
proportional hazards regression to evaluate associations between exposures and ovarian cancer risk based on 
aggressiveness.
16
 Follow-up time was calculated as the time between study entry and date of i) ovarian cancer 
diagnosis, ii) death, or iii) end of follow-up, whichever occurred first. Survivor function plots for exposures 
generally showed parallel curves, suggesting no relevant deviation from proportional hazards; the few 
deviations observed were due to small numbers of exposed cases within a specific category of aggressiveness. 
In primary analyses, we pooled data from all cohorts, and stratified by year of birth and cohort to account for 
potential differences in baseline hazards by these factors; associations were similar to those using random 
effects meta-analysis to combine cohort-specific estimates (data not shown). Statistical heterogeneity of 
associations across tumor aggressiveness categories was assessed via a likelihood ratio test comparing a model 
allowing the association for the risk factor of interest to vary by aggressiveness versus one not allowing the 
association to vary.
17
 A trend test was calculated across the ordinal aggressiveness subtype beta coefficients 
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of OC use, unless the exposure of interest was collinear with one of these factors. Hysterectomy analyses were 
additionally adjusted for HT use. For missing covariate data, we included a missing indicator in the model.  
We considered all invasive cases together and conducted analyses among serous/poorly differentiated 
tumors only and endometrioid/clear cell tumors; we combined these latter subtypes due to their similar risk 
factor profiles, as observed in our prior analysis.
10
 In an additional analysis, we evaluated endometrioid tumors 
separately; collapsed categories of aggressiveness were used due to limited sample size (i.e., highly/very 
aggressive: time between diagnosis and death <3 years; moderately/less aggressive: time between diagnosis and 
death or end of follow-up 3+ years). We also evaluated known high-grade serous tumors in a secondary 
analysis. We evaluated associations stratified by stage at diagnosis (stages 1 or 2 and stages 3 or 4) for all 
exposures for which we observed significant heterogeneity across aggressiveness categories. For BMI and 
smoking, we conducted sensitivity analyses excluding cases diagnosed within 2 years of baseline (to address 
potential for reverse causation), excluding all women with cardiovascular disease (CVD) or diabetes at baseline; 
for BMI, we also stratified by menopausal status and HT use. Two of the prospective cohort studies included in 
this study (AARP and NHS) were included in a previous study on tumor aggressiveness;
15
 these studies were 
excluded in a sensitivity analysis.  
We performed unsupervised hierarchical clustering of the four aggressiveness categories alone and 
further separated by histology (serous and endometrioid/clear cell) using beta estimates for exposures that had 
differential associations by tumor aggressiveness overall in invasive cases or within the serous or 
endometrioid/clear cell subsets using complete linkage and uncentered correlation (Pearson’s coefficient). SAS 
9.4 was used to conduct the analyses. A p-value of <0.05 was considered statistically significant.  
 
Results 
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During follow-up of 1,202,492 participants (1,298,977 including full cohort size for case-cohort studies), 4,584 
incident invasive epithelial ovarian cancers were identified which could be classified by tumor aggressiveness. 
Case numbers ranged from 1,009 for breastfeeding to 4,529 for smoking status (Table S1). This study included 
2,795 (73.6% of cases with known histology) serous, 506 (13.3%) endometrioid, 289 (7.6%) mucinous, and 208 
(5.5%) clear cell carcinomas. Fifteen of 21 cohorts were based in North America, four in Europe, one in 
Australia, and one in Asia (Table 1); a majority of the cohorts started enrollment in the 1990s. The median age 
at diagnosis was 71.0 years for highly aggressive (death <1 years following diagnosis), 67.5 years for very 
aggressive (death 1-<3 years), 65.6 years for moderately aggressive (death 3-<5 years), and 62.7 years for less 
aggressive (lived at least 5 years). The majority of participants with known stage were diagnosed with distant 
(stage 3-4) disease, with little variation in the moderately (75.6%), very (76.2%) and highly aggressive (76.2%) 
subgroups, but a smaller proportion of women with less aggressive disease diagnosed at later stage (41.8% 
distant) (Table S2). 
Associations of putative and established risk factors  
Parity (phet=0.01), family history of ovarian cancer (phet=0.02), adult BMI (phet≤0.04), and smoking status 
(phet<0.01) were differentially associated with risk of ovarian cancer by disease aggressiveness (Table 2). Both 
higher parity and family history of ovarian cancer were most strongly associated with less aggressive disease, 
though in opposing directions, whereas very high and very low BMI and current smoking at baseline were both 
more strongly associated with increased risk of highly aggressive disease. 
Specifically, a first child (i.e., parity of 1) conferred significant protection against highly and very aggressive 
disease, relative to nulliparity (e.g., highly aggressive, HR: 0.72 [95% CI: 0.58-0.88]); subsequent pregnancies 
conferred no additional protection (per pregnancy, HR: 0.97 [0.92-1.02]). For less aggressive disease, both the 
first and subsequent pregnancies were associated with lower risk (first/single pregnancy, HR: 0.87 [0.74-1.01]; 
subsequent pregnancies, HR: 0.87 [0.83-0.91]); ptrend across aggressiveness categories=0.002). Family history of 
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increasing stepwise with lower aggressiveness (e.g., highly aggressive, HR: 0.70 [0.38-1.32]); less aggressive, 
HR: 1.94 [1.47-2.55];  ptrend_aggressiveness =0.01).  
In contrast higher BMI and current smoking were associated with higher risk of highly aggressive, but not less 
aggressive, disease (ptrend_aggressiveness, BMI ≥35 kg/m
2
 category=0.002; current smoking=0.002). Notably, 
relative to women in the normal weight category (BMI 20-<25 kg/m
2
), higher risk of highly aggressive disease 
was observed in women in both the lowest (<20 kg/m
2
; HR: 1.36 [1.04-1.77]) and highest (≥35 kg/m
2
; HR: 1.93 
[1.46-2.56]) BMI categories. This association was not affected by additional adjustment for smoking (e.g., <20 
kg/m
2
; HR: 1.36 [1.04-1.78]). 
We also observed a significant trend across aggressiveness categories for duration of HT use (>5 years; p=0.03) 
and family history of breast cancer (p=0.03), both suggestive of higher risk of less aggressive disease, and tubal 
ligation (p=0.02), suggestive of lower risk for less aggressive disease. However, the p for heterogeneity overall 
using the likelihood ratio test was not statistically significant (all p=0.12). No heterogeneity in associations was 
observed for the other examined risk factors. 
Analyses in Histologic Subgroups 
We next evaluated the associations separately for (i) serous/poorly differentiated (n=2,795; Table S3), (ii) high-
grade serous disease (data not shown), and (iii) endometrioid /clear cell (n=714; Table S4). In a sensitivity 
analysis, we evaluated endometrioid tumors separately using collapsed aggressiveness categories (i.e., 
very/highly aggressive and less/moderately aggressive) (Table S5). Overall, results were of similar magnitude 
and in the same direction as those observed for invasive ovarian cancer overall. Among cases of 
endometrioid/clear cell disease, we observed a significant trend across aggressiveness categories for one height 
category (<1.60 meters; p=0.01); however, the p for overall heterogeneity for height was not statistically 
significant (p=0.28). Restricting the analysis to endometrioid disease, taller height appeared to be significantly 
associated with higher risk of more aggressive, but not less aggressive, disease (per 0.05 meters, phet=0.04), 
although the association with height as a categorical variable was not consistent with a linear association. For 
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disease while no association was observed with less aggressive disease (phet=0.01). Finally, current (vs. never) 
smoking was associated with significantly lower risk of less aggressive endometrioid cancers (phet<0.01). In 
analyses restricted to high-grade serous disease, heterogeneity by aggressiveness was statistically significant for 
duration of HT use (phet=0.02), with longer duration associated with significantly higher risk of disease in all 
aggressive subgroups except highly aggressive (e.g., >5 years vs. never, less aggressive, HR: 2.25 [1.76-2.89]; 
highly aggressive, HR: 0.98 [0.64-1.50]). 
Sensitivity Analyses 
We conducted sensitivity analyses for parity, family history of ovarian cancer, BMI and smoking to evaluate 
associations by stage at diagnosis (data available for >75% of cases; Tables S6-S8). For BMI and smoking, we 
conducted additional sensitivity analyses excluding cases diagnosed within 2 years of baseline or diagnosed 
with CVD or diabetes at baseline; we further evaluated BMI associations by menopausal status at baseline and 
for postmenopausal women by HT use, as well as HT associations stratified by BMI (<25 vs. ≥25 kg/m
2
) (data 
not shown). Patterns of association were similar for these subgroups, with the exception of analyses restricted to 
women diagnosed at stages 1 or 2, in which the associations of both BMI and smoking with highly aggressive 
disease, and family history of ovarian cancer and less aggressive disease, were attenuated. Further, in analyses 
restricted to stages 3 or 4, the association for parity and less aggressive disease was attenuated. Results were 
similar after excluding the two studies (AARP and NHS) included in a prior investigation on risk factors for 
ovarian cancer by aggressiveness (data not shown). 
After adjusting for multiple comparisons using Bonferroni correction for 17 tests, none of the phet remained 
statistically significant. However, the ptrend across aggressiveness categories for parity, BMI (≥35 kg/m
2
 
category), and current smoking met the stricter p<0.003 criterion.  
We further considered clustering of risk factor associations by disease aggressiveness alone and when further 
stratifying by histology (Figure 1). Overall, the risk factor profile for highly aggressive disease was distinct 
from the other aggressiveness categories (Figure 1a). Further, risk factor associations for highly aggressive and 
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subtypes tended to cluster by histology (e.g., less/moderately aggressive and very aggressive serous disease, and 
less/moderately aggressive and highly aggressive non-serous disease). Certain risk factors, such as age at 
menopause and having more than one child, tended to be more strongly associated with one histotype (e.g., non-
serous tumors) regardless of disease aggressiveness.  
Discussion 
We identified parity, family history of ovarian cancer, BMI, and smoking as risk factors that were differentially 
associated with ovarian cancer defined by subgroups of tumor aggressiveness, overall and within specific 
histologic subtypes, in this first large-scale, prospective investigation. Notably, high BMI and smoking, two 
modifiable risk factors, were most strongly associated with higher risk of the most aggressive, rapidly fatal, 
ovarian cancers. Further, clustering analysis showed that risk factor profiles for the most aggressive categories 
(i.e., highly and very aggressive disease) largely tracked by tumor aggressiveness rather than histology. Risk 
factors differentially impacting risk by subtype may act via their influence on: (i) whether an aggressive disease 
subtype develops; (ii) whether an already initiated malignancy develops toward an aggressive phenotype; 
and/or, (iii) prognostic factors, independent of the etiologic process (e.g., efficacy of chemotherapy, surgery).  
The first pregnancy was inversely associated with risk of more aggressive ovarian cancer; however, the inverse 
association for pregnancies beyond the first was stronger for less aggressive disease. The first pregnancy is 
associated with long-term permanent alterations in hormone regulation, including circulating lower prolactin 
levels;
18, 19
 higher circulating prolactin has been associated with ovarian cancer risk.
20
 This may impact etiology 
of all tumor types similarly. In contrast, more recent pregnancy may lead to a clearance of premalignant or 
malignant cells (i.e., a “wash out” effect).
21
 This may be more relevant for slowly progressing tumors (i.e., 
developing over a period of years), than rapidly progressing disease that is more likely to have developed in the 
interval since pregnancy. That said, there was no clear pattern of association for age at last birth and ovarian 
cancer risk by aggressiveness (regardless of adjustment for parity), although relatively few studies had these 
data (data not shown). Parity-related reductions in ovulatory cycles
22
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heterogeneity, given we observed no differences by aggressiveness for oral contraceptive use, or ages at 
menarche or menopause, all contributors to the number of lifetime ovulatory cycles.   
Family history of ovarian cancer was most strongly associated with less aggressive ovarian cancer, with a 
similar trend observed for family history of breast cancer. This is consistent with prior investigations suggesting 
a survival benefit proximal to diagnosis for women carrying an inherited BRCA  mutation,
23, 24
 potentially due 
to better response to platinum-based chemotherapies and PARP inhibitors.
25
 This survival benefit is evident in 
the relative short term after diagnosis (i.e., 3-5 years),
23
 as would be captured in our moderately and less 
aggressive disease categories. 
Higher BMI was positively associated with risk of highly aggressive ovarian cancer, but not less aggressive 
disease. The association between BMI and ovarian cancer did not differ by aggressiveness in the study by Poole 
et al.;
15
 however, results on ovarian cancer survival are in line with our findings.
25, 26
 Obesity may potentiate an 
ovarian cancer toward an aggressive pathway via its impact on the metabolic milieu, or may influence disease 
aggressiveness by providing a permissive local microenvironment for metastases, reducing efficacy of 
treatment, or poor post-surgical performance. The associations between BMI and adipokines, insulin resistance 
and the metabolic syndrome,
27
 and oxidative stress and chronic low-grade inflammation
28
 are well described; in 
turn, these factors have been hypothesized to be associated with ovarian cancer progression.
29-33
 Further, 
adiposity is associated with higher endogenous estrogen concentrations, as a result of an upregulation of 
aromatase activity,
34
 particularly in postmenopausal women.
35, 36
 However, the trends we observed for HT use 
were in the opposite direction of those observed for BMI, providing no support for endogenous estrogens as an 
intermediate mechanism. Omental adipose tissue has been identified as a tumor promoting microenvironment;
37
 
thus, this adipose depot proximate to the ovarian tumor may promote tumor progression and metastasis. In 
terms of treatment-related factors, suboptimal surgical cytoreductive (i.e., debulking) surgery and insufficient 
chemotherapy dosing may result in more rapidly fatal disease
38-41
 in obese women. Finally, we also observed 
that individuals with BMI less than 20 kg/m
2
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association was unchanged after adjustment for smoking. This should be confirmed in other studies and 
mechanisms explored to better understand this potential relationship.  
We observed suggestive heterogeneity in the associations between duration of postmenopausal HT use and 
tubal ligation and ovarian cancer risk by aggressiveness. The associations between HT use and tubal ligation did 
not differ by aggressiveness in the prior analysis by Poole et al.,
15
 nor are they consistently associated with 
survival.
25
 In the current study, longer duration of HT use was more strongly associated with increased risk of 
less aggressive disease. Data on circulating sex steroid hormones suggest heterogeneity by disease subtype, with 
a study in the OC3 reporting significantly different associations between circulating pre-diagnosis endogenous 
androgens and ovarian cancer risk by the dualistic pathway.
42
 Higher androgen concentrations increased risk of 
type I (less aggressive) ovarian cancer risk, but not type II (more aggressive) disease, providing indirect support 
for our findings. Androgens are a substrate for estrogen production, and are correlated in postmenopausal 
women (e.g. testosterone and estradiol, postmenopausal women, r=0.23-0.38).
43, 44
  
Current smoking was associated with highly aggressive, but not less aggressive, disease in this study. Smoking 
may drive development of a more aggressive phenotype via its well-described inflammation- and oxidative 
stress-inducing effects
45





). Further, limited data suggest that smoking may impact the effectiveness of neoadjuvant 
therapy,
47
 particularly for mucinous tumors. This is in agreement with observed differences between smoking 
and ovarian cancer mortality by histology in OCAC,
46
 with the strongest associations between smoking and 
mortality observed for mucinous disease. We observed similar associations in serous and endometrioid/clear 
cell subgroups in the current study; case numbers precluded evaluating smoking by aggressiveness among 
mucinous cases. 
We hypothesized that pre-diagnosis exposures may influence whether ovarian cancers develop toward “less” vs. 
“more” aggressive phenotypes, defined by survival time following an ovarian cancer diagnosis. Overall, results 
were similar by histologic subgroups, suggesting the observed heterogeneity was not principally driven by 
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and very aggressive disease track more clearly by tumor aggressiveness rather than by histology. This suggests 
that metrics of tumor heterogeneity beyond histotype should be evaluated to identify potential etiologic 
mechanisms that relate risk factors to disease development. For example, Kurman and colleagues suggested that 
ovarian cancer develops along two pathways: type I disease, a less aggressive phenotype including low grade 
serous, endometrioid, mucinous, clear cell, and malignant Brenner tumors, and; type II disease, more aggressive 
disease, primarily including high grade serous tumors.
48, 49
 Prognosis for type I tumors is significantly better 
than that observed for type II disease.
5, 50
 An alternative, complementary, approach to that implemented here 
would be to evaluate risk by the proposed dualistic model,
48
 classifying tumors using histology and grade. 
However, grade data were not available for a large portion of cases in this study.  
We conducted analyses by stage at diagnosis for exposures where we observed significant heterogeneity by 
aggressiveness to explore whether the observed results were due to associations between the exposure and later 
stage at diagnosis (e.g., if smoking status were more strongly associated with highly aggressive disease due to 
delayed detection and/or diagnosis). For BMI, family history of ovarian cancer, and smoking, patterns observed 
in the overall analysis were consistently observed for cases diagnosed at higher stage (stages 3 or 4; 63% of the 
study population). However, while data on stage at diagnosis were relatively complete, data on sub-stage were 
not available. As one example, the association between current smoking and highly aggressive disease was 
limited to women diagnosed at stage III/IV. It is possible that a higher proportion of smokers were diagnosed at 
more advanced sub-stage (e.g., IIIB, IIIC) than nonsmokers, explaining the association. A further limitation of 
this investigation is the lack of detailed information on comorbidities and lack of data on post-diagnosis 
treatment information, including chemotherapy regimen and debulking status. Poole et al.
15
 observed minimal 
impact on the differences between rapidly fatal vs. less aggressive disease before and after adjusting for both 
chemotherapy regimen and debulking status, suggesting that these factors may not be important covariates in an 
analysis of risk of ovarian cancer by tumor aggressiveness. The aggressiveness classification was based on 
death from any cause, as data on ovarian-cancer specific death were not readily available. We evaluated cause 
of death following ovarian cancer diagnosis in the NHS/NHSII, NLCS and EPIC cohorts, and the large majority 
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diagnosis (percentages of deaths due to ovarian cancer: highly aggressive: >90%; very aggressive >85%, 
moderately aggressive >83%, less aggressive >50%). Finally, despite the relatively large sample size, data 
availability for the investigated risk factors varied by cohort and was limited for some exposures (e.g., 
endometriosis, duration of breastfeeding) and analyses by disease aggressiveness within histologic subgroups 




We provide novel data on risk factors for ovarian cancer by aggressiveness, defined by time to death, in 
this pooled analysis in the OC3, identifying obesity and current smoking as modifiable risk factors 
predominantly associated with higher risk of highly aggressive (i.e., rapidly fatal) ovarian cancer. Further 
research is required to more fully describe the mechanistic pathways underlying these associations. However, 
our study supports a role for maintaining healthy weight and smoking cessation in reducing risk of ovarian 
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Figure 1.  
 
Unsupervised hierarchical clustering of ovarian cancer subtypes defined by disease aggressiveness using β-
estimates, with complete linkage and uncentered correlation (Pearson coefficient). Unsupervised hierarchical 
clustering of (A) aggressiveness categories and (B) aggressiveness further categorized by serous vs. non-serous 
histology . Aggressiveness categories defined as: highly aggressive: death within <1 year of diagnosis; very 
aggressive; death in 1-<3 years; moderately aggressive: death in 3-<5 years; less aggressive: lived 5+ years.  
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Table 1. Characteristics of cohorts in the Ovarian Cancer Cohort Consortium 
    


























Adventist Health Study II AHS U.S. 2002-2007 39,014 53 8 2015 41 
Breast Cancer Detection Demonstration Project 
Follow-up Study 
BCDDP U.S. 1987-1989 36,168 61 9 1999 104 
California Teachers Study  CTS U.S. 1995-1999 43,744 50 15 2012 151 
Campaign against Cancer and Stroke CLUEII U.S. 1989 12,380 46 22 2012 80 
Canadian Study of Diet, Lifestyle, and Health CSDLH Canada 1991-1999 2,733
b
 58 16 2010 78 
Cancer Prevention Study II Nutrition Cohort CPSII-NC U.S. 1992-1993 65,795 62 15 2009 444 
European Prospective Investigation into 
Cancer and Nutrition  
EPIC Europe 1992-2000 263,644 51 13 2010 519 
Iowa Women’s Health Study IWHS U.S. 1986 30,526 61 23 2010 252 
Melbourne Collaborative Cohort Study MCCS Australia 1990-1994 20,827 55 16 2009 86 
Multiethnic/Minority Cohort Study
c
 MEC U.S. 1993-1998 16,454 57 11 2011 55 
New York University Women’s Health Study NYU U.S. 1984-1991 12,407 49 24 2012 109 
Netherlands Cohort Study on diet and cancer NLCS Netherlands 1986 2,755
b
 62 17 2009 446 
NIH-AARP Diet and Health Study AARP U.S. 1995-1997 152,850 62 11 2006 504 
Nurses’ Health Study 1980
d
 NHS80 U.S. 1980-1982 86,624 46 16 2010 351 
Nurses’ Health Study 1996
d
 NHS96 U.S. 1996-1998 67,454 62 14 2010 342 
Nurses’ Health Study II NHSII U.S. 1989-1990 111,882 35 20 2011 159 
Prostate, Lung, Colorectal and Ovarian Cancer 
Screening Trial 
PLCO U.S. 1993-2002 60,103 62 12 2009 270 
Singapore Chinese Health Study SCHS Singapore 1993-1999 31,925 56 14 2011 81 
Swedish Mammography Cohort Study SMC Sweden 1997 34,388 60 14 2011 124 
VITamins And Lifestyle Cohort VITAL U.S. 2000-2002 28,297 60 10 2011 96 
Women’s Health Study WHS U.S. 1993-1996 33,518 53 18 2012 174 
Women's Lifestyle and Health WLHS Sweden 1991-1992 49,004 40 21 2012 118 
a
Stratified on birth year and cohort, and adjusted for age at study entry, parity, and duration of oral contraceptive use (except when parity or oral contraceptive use was the primary exposure of interest and 
then we adjusted only for the other risk factor) using pooled analyses of all cohorts combined.
 b
These cohorts were included as a case-cohort design, reflecting a total cohort population of 39,445 women 
for the CSDLH and 62,528 women for the NLCS. Appropriate weights for subcohort selection were applied in all analyses;  
c
Including only Caucasian women; 
d
The Nurses’ Health Study was broken into 

















HR (95% CI) 
Very 
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HR (95% CI) 
Moderately 
aggressive 
HR (95% CI) 
Less 
aggressive 
HR (95% CI) 









Time between diagnosis and death <1 year 1 to <3 years 3 to <5 years 5+ years   
Parity              
        No children 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)     
        First child 0.72 (0.58,0.88) 0.80 (0.67,0.94) 0.98 (0.76,1.28) 0.87 (0.74,1.01) 
0.01 
0.13 
        Subsequent children 0.97 (0.92,1.02) 0.94 (0.90,0.98) 0.95 (0.90,1.01) 0.87 (0.83,0.91) 0.002 
Age at first birth, per yr 0.99 (0.97,1.00) 1.00 (0.98,1.01) 0.99 (0.97,1.01) 1.01 (1.00,1.02) 0.19 0.08 
        <20 1.13 (0.85,1.50) 1.07 (0.86,1.33) 1.05 (0.78,1.41) 1.01 (0.83,1.24) 
0.56 
0.54 
        20-<25 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
 
        25-<30 0.98 (0.81,1.17) 0.92 (0.80,1.05) 0.97 (0.79,1.19) 1.05 (0.92,1.19) 0.30 
        30+ 0.85 (0.65,1.10) 1.02 (0.84,1.23) 0.81 (0.60,1.09) 1.10 (0.93,1.31) 0.18 
Age at last birth, per yr 1.00 (0.97,1.02) 1.01 (0.99,1.03) 0.98 (0.95,1.00) 1.01 (0.99,1.03) 0.26 0.51 
        <25 1.31 (0.86,2.01) 0.96 (0.67,1.39) 1.01 (0.64,1.58) 0.89 (0.66,1.19) 
0.32 
0.20 
        25-<30 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)   
        30-<35 1.20 (0.88,1.62) 1.14 (0.90,1.43) 1.04 (0.75,1.43) 1.08 (0.89,1.31) 0.56 
        35+ 1.19 (0.85,1.68) 1.06 (0.82,1.39) 0.59 (0.37,0.92) 1.06 (0.84,1.33) 0.51 
Duration of breastfeeding, per yr
d
 0.96 (0.80,1.15) 0.82 (0.68,0.98) 1.00 (0.86,1.18) 0.97 (0.87,1.09) 0.24 0.48 
      Ever vs never 0.90 (0.58,1.39) 0.67 (0.48,0.93) 0.98 (0.59,1.61) 1.01 (0.77,1.33) 0.27 0.20 
Duration of oral contraceptive use, per 5 yr 0.89 (0.81,0.99) 0.82 (0.76,0.89) 0.87 (0.78,0.97) 0.82 (0.77,0.88) 0.48 0.38 
        Never 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
0.95 
  
        ≤1  0.91 (0.68,1.21) 0.90 (0.73,1.10) 1.03 (0.77,1.37) 1.02 (0.86,1.21) 0.31 
        >1-≤5  0.83 (0.65,1.06) 0.87 (0.73,1.03) 0.98 (0.77,1.24) 0.84 (0.73,0.98) 0.99 
        >5-≤10  0.74 (0.56,0.99) 0.66 (0.54,0.82) 0.80 (0.59,1.07) 0.76 (0.64,0.91) 0.52 
        >10  0.72 (0.52,1.01) 0.59 (0.45,0.77) 0.60 (0.41,0.88) 0.57 (0.46,0.72) 0.37 
Age at menarche, per 1 yr 0.99 (0.95,1.04) 0.97 (0.94,1.00) 1.01 (0.96,1.06) 0.97 (0.94,1.01) 0.64 0.78 
≤11  1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
0.13 
 
12 0.88 (0.70,1.10) 0.84 (0.71,0.99) 1.00 (0.78,1.28) 0.95 (0.82,1.10) 0.32 
13 0.96 (0.79,1.18) 0.86 (0.74,1.00) 1.14 (0.91,1.43) 0.90 (0.79,1.04) 0.98 
14 0.83 (0.65,1.06) 0.81 (0.67,0.98) 0.89 (0.67,1.19) 1.00 (0.85,1.18) 0.10 
≥15 0.99 (0.78,1.26) 0.83 (0.69,1.01) 1.11 (0.83,1.48) 0.75 (0.62,0.91) 0.17 
Age at menopause, per 5 yr 1.02 (0.94,1.12) 1.04 (0.97,1.11) 0.98 (0.89,1.09) 1.09 (1.02,1.16) 0.37 0.30 
                  ≤40 1.13 (0.83,1.54) 1.02 (0.79,1.33) 1.18 (0.81,1.71) 0.71 (0.54,0.95) 
0.51 
0.05 
                   >40-≤45 0.89 (0.67,1.19) 0.71 (0.55,0.90) 1.08 (0.77,1.51) 0.82 (0.65,1.03) 0.87 
                   >45-≤50 1.02 (0.85,1.23) 0.95 (0.82,1.10) 1.04 (0.83,1.31) 0.89 (0.77,1.03) 0.33 
                   >50-≤55 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)   
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Duration of hormone therapy use, per 1 yr
e
 1.03 (1.01,1.04) 1.03 (1.02,1.04) 1.05 (1.03,1.06) 1.04 (1.03,1.05) 0.27 0.12 
                        Never 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
0.12 
 
                  ≤5 years 0.92 (0.74,1.14) 1.18 (0.99,1.40) 1.29 (1.00,1.66) 1.26 (1.06,1.47) 0.05 
                  >5 years 1.26 (1.01,1.58) 1.52 (1.28,1.80) 1.87 (1.47,2.39) 1.69 (1.43,1.99) 0.03 
Tubal ligation, ever vs. never 0.94 (0.65,1.36) 0.95 (0.75,1.21) 0.78 (0.55,1.11) 0.66 (0.53,0.82) 0.12 0.02 
Hysterectomy, ever vs. never
f
 0.88 (0.73,1.06) 0.83 (0.72,0.97) 1.09 (0.89,1.34) 0.92 (0.80,1.06) 0.21 0.36 
Endometriosis, ever vs. never 1.41 (0.66,3.00) 1.07 (0.59,1.95) 1.41 (0.75,2.68) 1.58 (1.06,2.33) 0.76 0.46 
Family history of breast cancer, yes vs. no 0.88 (0.70,1.11) 1.08 (0.91,1.28) 1.21 (0.95,1.54) 1.21 (1.04,1.41) 0.12 0.03 
Family history of ovarian cancer, yes vs. 
no 0.70 (0.38,1.32) 1.45 (1.04,2.04) 1.62 (1.01,2.60) 1.94 (1.47,2.55) 0.02 
0.01 
BMI in adulthood, per 5kg/m
2
 1.15 (1.07,1.23) 1.04 (0.98,1.10) 1.03 (0.95,1.12) 0.99 (0.94,1.04) 0.01 0.002 
       <20 1.36 (1.04,1.77) 1.02 (0.81,1.27) 0.98 (0.71,1.36) 0.94 (0.78,1.15) 
0.04 
0.06 
20-<25 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
 
25-<30 1.15 (0.98,1.35) 0.99 (0.87,1.12) 0.94 (0.78,1.13) 0.95 (0.85,1.07) 0.10 
30-<35 1.34 (1.07,1.67) 0.96 (0.80,1.16) 1.10 (0.85,1.42) 0.96 (0.81,1.14) 0.07 
≥35 1.93 (1.46,2.56) 1.34 (1.07,1.69) 1.01 (0.70,1.45) 0.98 (0.78,1.24) 0.0002 
BMI at age 18-20, per 5kg/m
2
 1.11 (0.97,1.28) 1.06 (0.95,1.19) 1.01 (0.86,1.18) 0.97 (0.87,1.08) 0.45 0.10 
              
<18 1.04 (0.76,1.42) 0.84 (0.64,1.11) 0.83 (0.57,1.21) 1.04 (0.83,1.3) 
0.62 
0.71 
18-<20 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)   
20-<22 1.09 (0.87,1.36) 1.05 (0.87,1.25) 0.84 (0.65,1.10) 1.06 (0.91,1.24) 0.79 
≥22 1.04 (0.83,1.31) 0.99 (0.82,1.19) 1.01 (0.78,1.31) 0.93 (0.79,1.10) 0.46 
Height, per 0.05m 1.06 (1.01,1.12) 1.09 (1.04,1.13) 1.04 (0.98,1.10) 1.07 (1.03,1.11) 0.71 0.86 
       <1.60m 0.81 (0.67,0.98) 0.89 (0.76,1.03) 0.88 (0.70,1.09) 0.94 (0.82,1.07) 
0.70 
0.30 
1.60-<1.65m 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 
 
1.65-<1.70m 0.90 (0.75,1.08) 1.05 (0.91,1.21) 1.07 (0.87,1.31) 1.10 (0.97,1.26) 0.12 
≥1.70m 1.13 (0.93,1.37) 1.21 (1.04,1.41) 1.05 (0.83,1.32) 1.11 (0.97,1.28) 0.63 
Smoking              
       Never 1.00 (ref.) 1.00 (ref.) 1.00 (ref.) 1.00 (ref.)     
       Former 0.91 (0.77,1.08) 1.07 (0.95,1.21) 1.02 (0.85,1.22) 0.95 (0.85,1.07) 
0.004 
0.79 
       Current 1.30 (1.07,1.57) 1.00 (0.85,1.17) 0.78 (0.60,1.01) 0.88 (0.76,1.02) 0.002 
a
Stratified on birth year and cohort, and adjusted for age at study entry, parity, and duration of oral contraceptive use (except when parity or oral contraceptive use was the primary exposure of interest and then 
we adjusted only for the other risk factor) using pooled analyses of all cohorts combined; 
b
Assessed using a likelihood ratio test comparing a Cox proportional hazards competing risks model allowing the 
association to vary by subtype to a model forcing the association to be the same across subtypes; 
 c
Trend across the ordinal aggressiveness subtypes using meta-regression with a subtype-specific random 
effect term; 
 d
Parous women only; 
 e
Postmenopausal women only; 
 f
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